Lab
L&L Diagnostics LLC
L&L Diagnostics LLC was paid $1.63M by Medicaid between Jul 2023 and Oct 2024, across 52 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 34% of everything it billed.
33Billing provider infoL&L DIAGNOSTICS LLC
COVINA, CA 91722
COVINA, CA 91722
33aNPI1821679317assigned 04/16/2021
33bProvider typeClinical Medical Laboratory
28Total paid$1.63M
24GClaims83,053
24DCodes billed52
24AFirst – last monthJul 2023 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#159 of 561
Median peer was paid$222K
This provider vs. median7.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 30,092 | $455K | |
| 2024incomplete | 52,961 | $1.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 34% | 3,921 | 3,635 | $551K |
| 87481 | 11% | 3,460 | 3,295 | $172K | |
| 83970 | 4.2% | 1,999 | 1,997 | $68K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.2% | 2,367 | 2,364 | $52K |
| 82670 | 3.0% | 2,006 | 2,002 | $48K | |
| 84403 | 2.8% | 2,056 | 2,053 | $46K | |
| 84402 | 2.7% | 2,037 | 2,034 | $45K | |
| 87640 | 2.6% | 3,391 | 3,279 | $43K | |
| 87653 | 2.6% | 2,891 | 2,838 | $42K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 2.4% | 2,041 | 1,980 | $39K |
| 82627 | 2.3% | 2,000 | 1,998 | $38K | |
| 84270 | 2.2% | 1,987 | 1,986 | $36K |
40 more codes
| 84144 | 2.2% | 2,000 | $36K | |
| 84443 | Thyroid stimulating hormone (TSH) | 2.1% | 2,387 | $34K |
| 83002 | 2.0% | 1,997 | $32K | |
| 82607 | 1.9% | 2,342 | $30K | |
| 82746 | 1.8% | 2,338 | $30K | |
| 83003 | 1.8% | 1,982 | $29K | |
| 80061 | Lipid panel | 1.7% | 2,507 | $28K |
| 84481 | 1.6% | 2,054 | $27K | |
| 82728 | 1.5% | 2,052 | $24K | |
| 84146 | 1.3% | 1,292 | $22K | |
| 80053 | Comprehensive metabolic panel | 1.3% | 2,419 | $22K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 2,541 | $21K |
| 84439 | <1% | 2,104 | $16K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,415 | $16K |
| 83550 | <1% | 2,186 | $15K | |
| 83735 | <1% | 2,227 | $13K | |
| 83540 | <1% | 2,162 | $12K | |
| 84153 | <1% | 746 | $12K | |
| 82533 | <1% | 713 | $10K | |
| 84550 | <1% | 2,212 | $9K | |
| 81001 | <1% | 2,307 | $6K | |
| 82043 | <1% | 1,102 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $1K |
| 87634 | <1% | 824 | $730.02 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 847 | $704.35 |
| 82570 | <1% | 146 | $648.67 | |
| 87529 | <1% | 849 | $626.25 | |
| 87150 | <1% | 1,265 | $484.05 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 828 | $423.88 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 481 | $304.77 |
| 87498 | <1% | 849 | $286.63 | |
| 87486 | <1% | 835 | $286.63 | |
| 87541 | <1% | 834 | $286.63 | |
| 87581 | <1% | 837 | $286.63 | |
| 82248 | <1% | 56 | $241.45 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $240.72 |
| 85730 | <1% | 12 | $63.48 | |
| 85610 | <1% | 12 | $41.52 | |
| 86592 | <1% | 12 | $37.80 | |
| 80050 | General health panel | 0% | 99 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEE, GIA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Chabado Genomics INC | Torrance, CA | $325K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.